Hansen Paul R. 4
4 · Vyant Bio, Inc. · Filed Apr 1, 2021
Insider Transaction Report
Form 4
Vyant Bio, Inc.VYNT
Hansen Paul R.
Director
Transactions
- Other
Common Stock, $0.0001 par value
2021-03-30+592,548→ 592,548 total - Other
Common Stock, $0.0001 par value
2021-03-30+65,000→ 65,000 total(indirect: By Trust) - Award
Stock option (right to buy)
2021-03-30+13,015→ 13,015 totalExercise: $4.61From: 2021-03-30Exp: 2031-03-30→ Common Stock (13,015 underlying)
Footnotes (1)
- [F1]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.